Ekaterina S. Voronina

Dr. Ekaterina S. Voronina

Research Centre for Medical Genetics, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Melanoma Research
Verified
Journal Article
Closed access
IMIrina N. Mikhaylova
Irina N. Mikhaylova
DKDmitry A. Kovalevsky
Dmitry A. Kovalevsky
LMLidia F. Morozova
Lidia F. Morozova
VGValentina A. Golubeva
Valentina A. Golubeva
ECEugene A. Cheremushkin
Eugene A. Cheremushkin
ABAnatoly Y. Baryshnikov
Anatoly Y. Baryshnikov
We analyzed the expression of 15 cancer/testis and four melanoma differentiation antigens in 21 metastatic melanoma cell lines using reverse transcriptase-polymerase chain reaction (RT-PCR) assay. On the basis of morphological characteristics, tumor cell lines were divided into three groups with high, moderate, and low grade of differentiation. Evaluation of gene expression and melanoma cell morphology has revealed a correlation between increased expression of cancer/testis genes and differentiation grade of cancer cells. The gene expression pattern for lymph node metastases and primary tumors exhibits the distribution of expression level and frequency similar to that found for established cell lines. Nevertheless, only 60% lymph node metastases or primary tumor tissue of randomly selected patients show marked expression of the most prominent cancer/testis genes, and almost 90% lesion tissue expresses at least one of 15 cancer/testis genes.

1 January 2007 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
NBN. P. Bochkov
N. P. Bochkov
EVEkaterina S. Voronina
Ekaterina S. Voronina
NKN. V. Kosyakova
N. V. Kosyakova
Thomas LiehrThomas Liehr
Thomas Liehr
ARA. A. Rzhaninova
A. A. Rzhaninova
DGD. V. Gol’dShtein
D. V. Gol’dShtein

11 November 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSSvetlana Smirnikhina
Svetlana Smirnikhina
EKEkaterina V. Kondrateva
Ekaterina V. Kondrateva
EAElmira P. Adilgereeva
Elmira P. Adilgereeva
AAArina A. Anuchina
Arina A. Anuchina
MZMilyausha I. Zaynitdinova
Milyausha I. Zaynitdinova
ALAlexander V. Lavrov
Alexander V. Lavrov
Development of genome editing methods created new opportunities for the development of etiology-based therapies of hereditary diseases. Here, we demonstrate that CRISPR/Cas9 can correct p.F508del mutation in theCFTRgene in the CFTE29o- cells and induced pluripotent stem cells (iPSCs) derived from patients with cystic fibrosis (CF). We used several combinations of Cas9, sgRNA and ssODN and measured editing efficiency in the endogenousCFTRgene and in the co-transfected plasmid containing theCFTRlocus with the p.F508del mutation. The non-homologous end joining (NHEJ) frequency in theCFTRgene in the CFTE29o- cells varied from 1.25% to 2.54% of alleles. The best homology-directed repair (HDR) frequency in the endogenousCFTRlocus was 1.42% of alleles. In iPSCs, the NHEJ frequency in theCFTRgene varied from 5.5% to 12.13% of alleles. The best HDR efficacy was 2.38% of alleles. Our results show that p.F508del mutation editing using CRISPR/Cas9 in CF patient-derived iPSCs is a relatively rare event and subsequent cell selection and cultivation should be carried out.

1 May 2021 in Stem Cell Research
Verified
Journal Article
Open access
EKEkaterina Kondrateva
Ekaterina Kondrateva
ADAnna Demchenko
Anna Demchenko
YSYana Slesarenko
Yana Slesarenko
MYMatvey Yasinovsky
Matvey Yasinovsky
EAElena Amelina
Elena Amelina
SSSvetlana Smirnikhina
Svetlana Smirnikhina
Cystic fibrosis is one of the most common inherited diseases caused by mutations in CFTR gene, of which F508del is the most frequent. Currently, the possibility of cell therapy including genome editing is widely discussed. We generated induced pluripotent stem cells from fibroblasts obtained from a 22-year-old woman with clinically manifested and genetically proven disease by using non-viral, non-integrating RNA reprogramming vector that contains five reprogramming factors: OCT4, KLF4, SOX2, GLIS1, and c-MYC. The established cell line can express endogenous pluripotency markers, possesses a normal karyotype, and has the ability to differentiate into three germ layers in spontaneous differentiation assay.

19 August 2023 in Chromosome Research
Verified
Journal Article
Closed access
PDF file
AKAnastasiia Kislova
Anastasiia Kislova
DZDiana Zheglo
Diana Zheglo
VPVictoria Pozhitnova
Victoria Pozhitnova
PSPhilipp Sviridov
Philipp Sviridov
EGElmira P. Gadzhieva
Elmira P. Gadzhieva
EVEkaterina S. Voronina
Ekaterina S. Voronina

Verified
Journal Article
Open access
PDF file
DZDiana Zheglo
Diana Zheglo
VPVictoria Pozhitnova
Victoria Pozhitnova
AKAnastasiia Kislova
Anastasiia Kislova
ZMZhanna Markova
Zhanna Markova
DKDanila Kiselev
Danila Kiselev
EVEkaterina S. Voronina
Ekaterina S. Voronina
Genome instability in induced pluripotent stem cells (IPSC) poses a significant challenge for their use in research and medicine. Cataloging and precisely describing all the identified aberrations that arise during cell reprogramming, expansion, and differentiation is essential for improving approaches to instability prevention and ensuring genetic quality control. We report the karyotypic analysis of 65 cell lines derived from skin fibroblasts, urinal sediment, and peripheral blood mononuclear cells of 33 individuals, 82% of whom suffer from monogenic genetic disorders not associated with genetic instability. Trisomy of chromosomes 20 and 8 was revealed recurrently, while the 1q arm was the most frequently affected region involved in interstitial duplications and unbalanced translocations with chromosomes 15 and 18. The localization of rearrangement breakpoints identified by SNP arrays within the large DCC gene and histone gene clusters links genetic instability in IPSCs to replication-stress-induced chromosome breakage at common and early replicating fragile sites.